Loading viewer...
investor_presentation
Format: PDF investor_presentation
Ironwood Pharmaceuticals presented its Q1 2022 investor update on May 5, 2022, detailing strategic priorities around maximizing LINZESS sales, advancing its GI pipeline, and developing new treatments including CNP-104 for primary biliary cholangitis and IW-3300 for visceral pain conditions. The company outlined efforts to drive sustained profits and cash flow while strengthening intellectual property protection for its lead gastrointestinal franchise.
investor_presentation
25 Pages
Unknown